Physician

Michael Vincent Florendo Tablang, M.D.

According to 2025 Medicare claims, Michael Tablang, M.D. (NPI: 1679763387) practices infectious disease in the Crestview-Fort Walton Beach-Destin, FL market, with the plurality of this provider's patient population coming from Okaloosa, FL. This provider's primary affiliated billing organization is EMERALD COAST INFECTIOUS DISEASES MEDICAL GROUP, P.A. (NPI: 1720017882; TIN: 562483799) and primary practice location at 32536-2727.

Tablang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,086 traditional Medicare patients, billed 878,822 HCPCS/CPT codes, and received $5,157,071 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 720 prescription claims across 186 beneficiaries totaling $594,554 in drug costs, led by Dovato (Dolutegravir Sodium/Lamivudine). 2021 DME data shows 50 claims. Open Payments data shows 23 records totaling $413. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $198,523 to $5,157,071. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $510,417 and ending at $594,554. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $5,129 and ending at $12,977.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	485	2,781	$198,523
2016	481	2,641	$188,312
2017	557	3,218	$226,143
2018	576	3,438	$254,902
2019	755	8,124	$262,636
2020	1,064	1,006,575	$1,131,756
2021	1,249	2,004,870	$2,197,097
2022	1,241	1,183,464	$2,053,649
2023	1,112	729,098	$2,666,564
2024	1,086	878,822	$5,157,071

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	89	339	$510,417
2016	105	313	$373,534
2017	118	580	$393,749
2018	133	638	$1,583,606
2019	110	452	$749,156
2020	130	643	$513,586
2021	145	767	$475,043
2022	195	752	$514,401
2023	206	835	$694,487
2024	186	720	$594,554

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	50	$14,334
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	374	451	$135
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	393	1,633	$97
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	625	1,930	$92
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	215	456	$61
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	208	2,032	$47

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dovato	Dolutegravir Sodium/Lamivudine	17	990	$92,151
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	21	630	$83,318
Prolia	Denosumab	19	3,420	$32,986
Daptomycin	Daptomycin	32	212	$10,132
Ertapenem	Ertapenem Sodium	16	97	$4,029

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$413	ViiV Healthcare Company
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael Vincent Florendo Tablang, M.D.?

Tedicare shows public-source Medicare data for Michael Vincent Florendo Tablang, M.D. (NPI 1679763387), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Vincent Florendo Tablang, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael Vincent Florendo Tablang, M.D.?

Michael Vincent Florendo Tablang, M.D. is linked to EMERALD COAST INFECTIOUS DISEASES MEDICAL GROUP, P.A. (billing NPI 1720017882) in the available physician profile data.

Does Michael Vincent Florendo Tablang, M.D. have Open Payments data?

Michael Vincent Florendo Tablang, M.D. has 23 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.